BIOSTAT STR generation 3 from Sartorius Stedim Biotech - single use bioreactor aims at flexible mid-scale runs

Reviewed: ad hoc news B2B & Pro desk. Edited and checked on 2026-06-27, 09:03. Details in the imprint.

BIOSTAT STR generation 3 from Sartorius Stedim Biotech sits in a clean white production suite, its film bag rustling quietly as air is pulled through before a batch starts. A gloved operator taps the touchscreen, feeling the slight vibration as the magnetic drive stirs the cell culture to life.

What BIOSTAT STR does

The BIOSTAT STR generation 3 platform is Sartorius Stedim Biotech's latest single use bioreactor line, designed for volumes from roughly 50 to 2,000 liters in upstream biopharmaceutical production. It targets biologics makers that want to avoid stainless steel cleaning cycles while keeping process control tight.

Each unit combines pre-sterilized, disposable Flexsafe STR bags with an integrated control tower that manages parameters such as pH, dissolved oxygen, temperature and agitation via advanced sensors. Operators can run fed-batch or perfusion processes with reduced turnaround time between campaigns.

How it feels on the floor

Walk up to a BIOSTAT STR generation 3 unit and the first thing you notice is the tidy footprint: a compact stainless frame, anchored bag support and a vertical control tower with a bright, sharp touchscreen. The hum of the integrated stirrer is surprisingly quiet, even at higher agitation rates.

Field engineers describe the Flexsafe STR bag film as robust yet smooth to the touch when they unfold it in the preparation room, with weld seams that sit flat instead of crinkling. That matters when operators like Marie Dubois, a bioprocess engineer at a French CDMO, load bags repeatedly under GMP pressure.

Why single use matters

Single use bioreactors like BIOSTAT STR generation 3 cut out cleaning validation and steam-in-place cycles that can add hours or days between batches in stainless steel systems. Instead, a used bag is removed and a fresh sterile bag is installed, reducing cross-contamination risk.

For smaller biologics firms and contract manufacturers, this flexibility can be convincing when demand is volatile. A suite equipped with multiple BIOSTAT STR units can switch between different monoclonal antibodies or recombinant proteins without lengthy downtime for cleaning and qualification runs.

Automation and data handling

The control tower on BIOSTAT STR generation 3 connects to Sartorius Stedim Biotech's broader automation environment, including SCADA systems and digital data historians. Operators can monitor trends for key variables and push alarm limits centrally rather than walking from unit to unit.

Recipe management allows process developers to define stepwise feeds, gas strategies and agitation profiles, then clone those recipes across multiple scales. That is helpful when a mid-scale 200-liter run needs to be mirrored quickly in a 2,000-liter bag for commercial production.

Integration with other Sartorius gear

BIOSTAT STR generation 3 does not stand alone in the plant. It typically pairs with Sartorius Stedim Biotech's single use mixing systems, depth filters and chromatography skids, forming a continuous upstream-downstream chain of disposable technologies.

This integration is practical for facilities that were originally designed as multipurpose. A common bag interface and shared sensor families mean operators can move between units with less re-training and fewer spare part variations to manage.

Where it shines and where it does not

On the strength side, BIOSTAT STR generation 3 offers a clean, self-assured control interface and high turn-around potential for multiproduct plants. The tactile feel of the controls and the smooth bag loading process often come up in user feedback from busy CDMO suites.

The limitations appear when ultra-high tank volumes or very high oxygen transfer are required, as stainless steel systems still dominate some large-scale blockbuster biologics plants. Waste handling for used bags also adds logistics considerations, especially in regions with strict incineration and recycling rules.

Regulatory and validation aspects

Sartorius Stedim Biotech designs BIOSTAT STR generation 3 in line with international guidelines for single use systems, giving users documentation for leachables and extractables from the bag materials. Validation teams can integrate this data into their risk assessments.

Regulators accept single use bioreactors widely for commercial biologics, but they expect robust control strategies. That is where the detailed sensor suites and software audit trails become central when preparing inspection dossiers for agencies in the US, EU or Asia.

Market position and competition

BIOSTAT STR generation 3 competes with other single use platforms from major bioprocess vendors, in a market that has shifted steadily toward disposable upstream systems over the past decade. Sartorius Stedim Biotech positions itself strongly in the mid-scale segment rather than only in small development labs.

Customers often weigh bag robustness, sensor reliability and software usability when choosing between suppliers. Feedback points to Sartorius Stedim Biotech's consistent focus on operator experience, from the layout of tubing ports to the visibility of alarms on the control screen.

Pricing and availability

As a B2B system, BIOSTAT STR generation 3 does not have a public retail price. Instead, Sartorius Stedim Biotech bundles hardware, bags and service contracts in project-specific quotations that depend on volume, configuration and region.

Availability is focused on biopharmaceutical hubs in Europe, North America and Asia, where Sartorius Stedim Biotech already supports large installed bases of earlier BIOSTAT STR generations. New greenfield plants often consider the latest generation during design, to avoid retrofits later.

Not a product for Amazon

Unlike a benchtop lab gadget, BIOSTAT STR generation 3 is an industrial bioprocess system and therefore not listed as a regular item on consumer platforms such as amazon.de. Procurement runs through direct vendor relationships and validated supply chains.

For investors and technical buyers, the main information channels are manufacturer documentation, trade fairs and specialist reviews, rather than common online retail listings. That shapes how visibility for the product translates into sales and eventually into reported revenue.

Company context and shares

All told, BIOSTAT STR generation 3 underscores Sartorius Stedim Biotech's strategy of leaning into single use technologies for biologics manufacturing and offering complete process chains around them. This focus keeps the group aligned with the long-range trend toward flexible, modular biopharma plants, which matters for investors as well.

Sartorius Stedim Biotech shares (ISIN FR0013154002) trade primarily on Euronext Paris, giving international investors a liquid entry point into the company's bioprocess portfolio without direct exposure to individual products like BIOSTAT STR generation 3.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.

en | FR0013154002 | SARTORIUS STEDIM | boerse | 69637770 | bgmi